Capri Holdings Ltd vs Merck & Co., Inc. — how do they compare? Capri Holdings Ltd trades at $14.69 (market cap $1.67B), while Merck & Co., Inc. trades at $142.58 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 210.3× Capri Holdings Ltd's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Merck & Co., Inc. for 98 Days on average.
| CPRI | MRK | |
|---|---|---|
Market Cap | $1.67B | $351.28B |
Volume | 3,722,279 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $156.43 |
52-Week Low | $12.71 | $82.49 |
Typical Hold Time | 41 Days | 98 Days |
Enterprise Value | $2.95B | $398.04B |
Dividend Yield | — | 2.39% |
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.44, down 1.57% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $1.18 billion in 2025, though recent quarters have consistently beaten EPS estimates. Revenue has declined from $5.7 billion in 2022 to $4.44 billion in 2025, but management expects second-half growth driven by brand revitalization efforts at Michael Kors and Jimmy Choo.
The stock presents a mixed outlook with a low P/S ratio of 0.5 and a consensus price target of $20.57 offering potential upside. However, significant risks include persistent revenue declines, high debt levels, and competitive pressures in the luxury sector. Analyst sentiment is divided with 44% buy ratings versus 52% hold, reflecting uncertainty about the turnaround timeline.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →